SCHEMBL6316636

SCHEMBL6316636

COc1ccc(-c2noc(N)c2C(=O)NCCc2cccc(Cl)c2)cn1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.50
MAPT P10636 3/20 0.45
HTT P42858 2/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
PPARD Q03181 4/20 0.44
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
GAA P10253 1/20 0.43
THRB P10828 2/20 0.43
ALDH1A1 P00352 1/20 0.43
IDO1 P14902 1/20 0.42
POLB P06746 3/20 0.42
TP53 P04637 1/20 0.42
FYN P06241 1/20 0.42
BCL2 P10415 1/20 0.41
BCL2L1 Q07817 1/20 0.41
MCL1 Q07820 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6315498 0.91 POLB (0.52) MAPTNPC1ALDH1A1POLBFYN
SCHEMBL6324006 0.89 MAPT (0.48) HIF1AMAPTHTTMEN1KMT2A
SCHEMBL6324304 0.85 L3MBTL1 (0.53) MAPTHTTMEN1KMT2AGAA
SCHEMBL6317731 0.84 SMN1; SMN2 (0.51) MAPTHTTMEN1KMT2ASMN1; SMN2
SCHEMBL6317605 0.84 L3MBTL1 (0.57) MAPTHTTMEN1KMT2AGAA
SCHEMBL6324168 0.83 NPC1 (0.60) HIF1AMAPTHTTMEN1KMT2A
SCHEMBL6324039 0.81 ALDH1A1 (0.52) MAPTMEN1KMT2ARAB9AGAA
SCHEMBL6323798 0.81 GAA (0.45) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL6316080 0.81 ALDH1A1 (0.48) MAPTSMN1; SMN2GAATHRBALDH1A1
SCHEMBL6323609 0.81 ADORA2A (0.48) ALDH1A1POLBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 HIF1A 3267/4885MAPT 281/4885HTT 2134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.